Literature DB >> 30068594

Analysis of KIR3DP1 Polymorphism Provides Relevant Information on Centromeric KIR Gene Content.

Maria Bono1, Daniela Pende2, Alice Bertaina3, Alessandro Moretta4,5, Mariella Della Chiesa4,5, Simona Sivori4,5, Marco Zecca6, Franco Locatelli3, Lorenzo Moretta7, Cristina Bottino1,4, Michela Falco1.   

Abstract

Four killer cell Ig-like receptor (KIR) genes, collectively referred to as framework genes, characterize almost all KIR haplotypes. In particular, KIR3DL3 and KIR3DL2 mark the ends of the locus, whereas KIR3DP1 and KIR2DL4 are located in the central part. A recombination hot spot, mapped between KIR3DP1 and KIR2DL4, splits the haplotypes into two regions: a centromeric (Cen) region (spanning from KIR3DL3 to KIR3DP1) and a telomeric region (from KIR2DL4 to KIR3DL2), both varying in KIR gene content. In this study, we analyzed KIR3DP1 polymorphism in a cohort of 316 healthy, unrelated individuals. To this aim, we divided KIR3DP1 alleles into two groups by the use of a sequence-specific primer- PCR approach. Our data clearly indicated that KIR3DP1 alleles present on haplotypes carrying Cen-A or Cen-B1 regions differ from those having Cen-B2 motifs. Few donors (∼3%) made exceptions, and they were all, except one, characterized by uncommon haplotypes, including either KIR deletions or KIR duplications. Consequently, as KIR2DL1 is present in Cen-A and Cen-B1 regions but absent in Cen-B2 regions, we demonstrated that KIR3DP1 polymorphism might represent a suitable marker for KIR2DL1 gene copy number analysis. Moreover, because Cen-B1 and Cen-B2 regions are characterized by different KIR3DP1 alleles, we showed that KIR3DP1 polymorphism analysis also provides information to dissect between Cen-B1/Cen-B1 and Cen-B1/Cen-B2 donors. Taken together, our data suggest that the analysis of KIR3DP1 polymorphism should be included in KIR repertoire evaluation.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30068594     DOI: 10.4049/jimmunol.1800564

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.

Authors:  C Quintarelli; S Sivori; S Caruso; S Carlomagno; L Moretta; F Locatelli; M Falco; I Boffa; D Orlando; M Guercio; Z Abbaszadeh; M Sinibaldi; S Di Cecca; A Camera; B Cembrola; A Pitisci; M Andreani; L Vinti; S Gattari; F Del Bufalo; M Algeri; G Li Pira; A Moseley; B De Angelis
Journal:  Leukemia       Date:  2019-11-19       Impact factor: 11.528

Review 2.  Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.

Authors:  Daniela Pende; Michela Falco; Massimo Vitale; Claudia Cantoni; Chiara Vitale; Enrico Munari; Alice Bertaina; Francesca Moretta; Genny Del Zotto; Gabriella Pietra; Maria Cristina Mingari; Franco Locatelli; Lorenzo Moretta
Journal:  Front Immunol       Date:  2019-05-28       Impact factor: 7.561

3.  Haplotype-Based Analysis of KIR-Gene Profiles in a South European Population-Distribution of Standard and Variant Haplotypes, and Identification of Novel Recombinant Structures.

Authors:  Elisa Cisneros; Manuela Moraru; Natalia Gómez-Lozano; Aura Muntasell; Miguel López-Botet; Carlos Vilches
Journal:  Front Immunol       Date:  2020-03-17       Impact factor: 7.561

4.  Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches.

Authors:  Matteo Tanzi; Michela Consonni; Michela Falco; Federica Ferulli; Enrica Montini; Annamaria Pasi; Rosalia Cacciatore; Silvia Brugnatelli; Paolo Pedrazzoli; Marco Zecca; Stella Boghen; Paolo Dellabona; Giulia Casorati; Daniela Montagna
Journal:  Cancers (Basel)       Date:  2021-03-30       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.